Australian trial defines ideal prostate therapy
The finding means many men will be spared the long-term side effects linked to testosterone-suppression therapy
31st January 2019
Australian researchers believe they’ve hit on the optimum duration of hormone-suppression therapy for men with aggressive, localised prostate cancers after a 10-year trial.